Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
Stefan Sleijfer(Erasmus MC Cancer Institute), Jean‐Yves Blay(Centre Léon Bérard), M. Ouali(European Organisation for Research and Treatment of Cancer), Axel Le Cesne(Institut Gustave Roussy), M. van Glabbeke(European Organisation for Research and Treatment of Cancer), Jaap Verweij(Deutz (Germany)), Anders Krarup‐Hansen(Herlev Hospital), Sjoerd Rodenhuis(The Netherlands Cancer Institute), Pancras C.W. Hogendoorn(Leiden University Medical Center)
Cited by 246
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k